SARS-CoV-2 S Glycoprotein Stabilization Strategies.
Level 5 - mechanism / opinion, no new human data
Narrative review of structural biology and protein engineering strategies without primary human clinical trial data.
PubMed 36851772 · doi:10.3390/v15020558
What was done
The authors reviewed structural biology and protein engineering strategies developed prior to and during the COVID-19 pandemic to stabilize the SARS-CoV-2 spike (S) glycoprotein in its native prefusion conformation for vaccine development.
What was found
The abstract reports no quantitative data. It qualitatively notes that the native prefusion S trimer is metastable and that spontaneous conformational changes during entry expose off-target epitopes, reducing neutralizing antibody induction. Prefusion-stabilized S trimers provide superior protective efficacy compared to non-stabilized S antigens.
Why it matters
Structure-guided stabilization of viral glycoproteins directly informs rational vaccine antigen design by focusing humoral immunity on neutralizing epitopes.
Limits
This is a narrative review with no systematic search methodology, no quantitative meta-analysis, and no reported primary clinical trial data in the abstract.
Cited by
- supports All COVID-19 vaccines authorized in the US (Moderna, Pfizer-BioNTech, Johnson & Johnson, and Novavax) incorporate two proline substitutions (2P) to stabilize the spike protein in its pre-fusion conformation.